CAN 04

Drug Profile

CAN 04

Alternative Names: CAN04

Latest Information Update: 08 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Lund University
  • Developer Cantargia
  • Class Anti-inflammatories; Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Interleukin-1 receptor accessory protein inhibitors; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Breast cancer; Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer
  • Preclinical Solid tumours

Most Recent Events

  • 05 Jan 2018 Cantargia receives patent allowance for IL1RAP-targeting antibodies in China
  • 04 Jan 2018 Cantargia receives patent allowance for IL1RAP-targeting antibodies in USA
  • 13 Oct 2017 Phase-I/II clinical trials in Breast cancer (Late-stage disease, Metastatic disease, Combination therapy, Second-line therapy or greater) in Denmark, Norway, Belgium and Netherlands (IV) (NCT03267316)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top